Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.2
Journals
Microorganisms
Special Issues
Gut Microbiota in Health and Diseases: The Role of Pro-/Pre-/Syn-/Post-Biotics...
share announcement

Gut Microbiota in Health and Diseases: The Role of Pro-/Pre-/Syn-/Post-Biotics in the Gut–Liver–Brain Axis

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Gut Microbiota".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 7099

Special Issue Editors

Dr. Mohamad Khalil

E-Mail Website
Guest Editor
Clinica Medica “A. Murri”, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), Medical School, University of Bari Aldo Moro, 70124 Bari, Italy
Interests: polyphenols; nutritional phytochemicals; gut microbiota; metabolic disturbances; metabolism
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Piero Portincasa

grade E-Mail Website
Co-Guest Editor
Clinica Medica “A. Murri”, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), Medical School, University of Bari Aldo Moro, 70124 Bari, Italy
Interests: lipid metabolism; enterohepatic circulation; liver steatosis; gut microbiota; polyphenols
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Introduction: The gut microbiome is a diverse array of microorganisms residing in the gastrointestinal tract, forming a complex ecosystem vital for human health. It significantly influences numerous physiological processes, including digestion, metabolism, immune function, and mental health. Notably, the gut–liver–brain axis illustrates the interconnectedness of gut microbiota, metabolic processes, and mental health.

The gut–brain axis and gut metabolic axis are intricately interconnected pathways that illustrate the complex relationship between gut health, brain function, and metabolic processes. The gut–brain axis involves bidirectional communication between the gastrointestinal tract and the central nervous system, which influences mental health. Conversely, the gut–metabolic axis focuses on how gut health impacts metabolic functions, including nutrient absorption and the production of metabolites that regulate metabolism and energy balance. These two axes are linked through various mechanisms, including the influence of gut-derived neurotransmitters on metabolic processes, the impact of stress on gut microbiota composition, and the role of chronic inflammation from gut dysbiosis in affecting both brain function and metabolic health. Understanding these connections underscores the importance of gut health in promoting overall well-being, suggesting that interventions targeting the gut may benefit both mental and metabolic health.

This Special Issue seeks to enhance our understanding of gut–microbiota–brain interaction, essential for creating effective, holistic strategies for prevention and treatment. Investigating how changes in gut microbiota can influence mental and metabolic health outcomes may lead to innovative therapeutic approaches, such as personalized probiotics or dietary adjustments aimed at fostering these issues.

We invite manuscripts that present original research, reviews, and perspectives on all aspects of gut microbiota linked with mental and metabolic health, as well as regarding biotics such as pro-/pre-/syn-/post-biotics in gut–liver–brain axis disorders. Topics of interest include, but are not limited to, the following:

  • The impact of gut-derived metabolites on liver function and overall metabolism.
  • Probiotic modulation of the gut microbiome as a strategy for mitigating and preventing mental health disorders, as supported by clinical studies.
  • The gut–liver–brain axis focuses on how changes in microbiota can alter specific pathways related to gut metabolite production and mental illness.

Dr. Mohamad Khalil
Prof. Dr. Piero Portincasa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut microbiome
  • gut–liver–brain axis
  • gastrointestinal tract
  • digestion
  • metabolism
  • immune function

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

46 pages, 1703 KiB  
Article
Gut Microbiome Modulation and Health Benefits of a Novel Fucoidan Extract from Saccharina latissima: A Double-Blind, Placebo-Controlled Trial
by Gissel Garcia, Josanne Soto, Carmen Valenzuela, Mirka Bernal, Jesús Barreto, María de la C. Luzardo, Raminta Kazlauskaite, Neil Waslidge, Charles Bavington and Raúl de Jesús Cano
Microorganisms 2025, 13(7), 1545; https://doi.org/10.3390/microorganisms13071545 - 30 Jun 2025
Abstract
 This randomized, double-blind, placebo-controlled, three-arm clinical trial evaluated the effects of a proprietary bioactive fucoidan-rich extract derived from Saccharina latissima (SLE-F) on gut microbial composition and function in healthy adults. The objective of the study was to assess the potential of SLE-F to [...] Read more.
 This randomized, double-blind, placebo-controlled, three-arm clinical trial evaluated the effects of a proprietary bioactive fucoidan-rich extract derived from Saccharina latissima (SLE-F) on gut microbial composition and function in healthy adults. The objective of the study was to assess the potential of SLE-F to beneficially modulate the gut microbiome, with this paper specifically reporting on microbial diversity, taxonomic shifts, and functional pathway outcomes. Ninety-one participants received either a low dose (125 mg), high dose (500 mg), or placebo twice daily for four weeks. The primary endpoint was the microbiome composition assessed via 16S rRNA sequencing (V3–V4 region), with secondary outcomes including surveys, adverse event monitoring, and clinical evaluations. High-dose supplementation resulted in dose-dependent improvements in the microbial diversity; increased abundance of beneficial taxa, including Bifidobacterium, Faecalibacterium, and Lachnospiraceae; and reductions in inflammation-associated taxa, such as Enterobacteriaceae and Pseudomonadota. A functional pathway analysis showed enhancement in short-chain fatty acid biosynthesis and carbohydrate metabolism. The low-dose group showed modest benefits, primarily increasing Bifidobacterium, with limited functional changes. In vitro colonic simulations further demonstrated a dose-dependent increase in short-chain fatty acids and postbiotic metabolite production following SLE-F exposure. SLE-F was well tolerated, with only mild, nonspecific adverse events reported. These findings support the potential of SLE-F as a safe and effective microbiome-modulating agent, warranting further study of the long-term use and synergy with dietary interventions.  Full article
(This article belongs to the Special Issue Gut Microbiota in Health and Diseases: The Role of Pro-/Pre-/Syn-/Post-Biotics in the Gut–Liver–Brain Axis)

Review

Jump to: Research

41 pages, 2830 KiB  
Review
Unraveling the Role of the Human Gut Microbiome in Health and Diseases
by Mohamad Khalil, Agostino Di Ciaula, Laura Mahdi, Nour Jaber, Domenica Maria Di Palo, Annarita Graziani, Gyorgy Baffy and Piero Portincasa
Microorganisms 2024, 12(11), 2333; https://doi.org/10.3390/microorganisms12112333 - 15 Nov 2024
Cited by 14 | Viewed by 6802
Abstract
The human gut is a complex ecosystem that supports billions of living species, including bacteria, viruses, archaea, phages, fungi, and unicellular eukaryotes. Bacteria give genes and enzymes for microbial and host-produced compounds, establishing a symbiotic link between the external environment and the host [...] Read more.
The human gut is a complex ecosystem that supports billions of living species, including bacteria, viruses, archaea, phages, fungi, and unicellular eukaryotes. Bacteria give genes and enzymes for microbial and host-produced compounds, establishing a symbiotic link between the external environment and the host at both the gut and systemic levels. The gut microbiome, which is primarily made up of commensal bacteria, is critical for maintaining the healthy host’s immune system, aiding digestion, synthesizing essential nutrients, and protecting against pathogenic bacteria, as well as influencing endocrine, neural, humoral, and immunological functions and metabolic pathways. Qualitative, quantitative, and/or topographic shifts can alter the gut microbiome, resulting in dysbiosis and microbial dysfunction, which can contribute to a variety of noncommunicable illnesses, including hypertension, cardiovascular disease, obesity, diabetes, inflammatory bowel disease, cancer, and irritable bowel syndrome. While most evidence to date is observational and does not establish direct causation, ongoing clinical trials and advanced genomic techniques are steadily enhancing our understanding of these intricate interactions. This review will explore key aspects of the relationship between gut microbiota, eubiosis, and dysbiosis in human health and disease, highlighting emerging strategies for microbiome engineering as potential therapeutic approaches for various conditions. Full article
(This article belongs to the Special Issue Gut Microbiota in Health and Diseases: The Role of Pro-/Pre-/Syn-/Post-Biotics in the Gut–Liver–Brain Axis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop